Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:08:07.715Z.
Calculation as of: 2026-10-06T17:08:07.715Z.
Quote observation: 2026-10-06T17:03:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f972cfcdde9e4531ce3198b66662ffcb9080d57c966754dbe52ec7edaf14096
PEG RATIO
N/A
NervGen Pharma Corp. Common stock
Market Cap
$149.18M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $149.18M | N/A |
| LifeMD, Inc. (LFMDP)vs › | $148.31M | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $147.34M | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $146.42M | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | N/A |
| Codexis, Inc. (CDXS)vs › | $151.15M | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $152.06M | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.23M | N/A |
| Nyxoah S.A. (NYXH)vs › | $144.10M | N/A |
| Neuronetics, Inc. (STIM)vs › | $155.68M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
